H.C. Wainwright Downgrades Iterum Therapeutics (ITRM) to Neutral
H.C. Wainwright analyst Matthew Keller downgraded Iterum Therapeutics (NASDAQ: ITRM) from Buy to Neutral.The analyst comments "We are downgrading to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
(Premium-only article. Please sign in or upgrade to SI Premium to view.)